The global Choroidal Neovascularization Drug market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
In terms of production side, this report researches the Choroidal Neovascularization Drug production capacity, value, ex-factory price, growth rate, market share by manufacturers, regions (or countries) and by Type.
In terms of consumption side, this report focuses on the consumption of Choroidal Neovascularization Drug by regions (countries) and by Application.
The global Choroidal Neovascularization Drug market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of production analysis, the authors of the report have provided reliable estimations and calculations for global revenue and volume by Type segment of the global Choroidal Neovascularization Drug market. These figures have been provided in terms of both revenue and volume for the period 2016-2027. Additionally, the report provides accurate figures for production by region in terms of revenue as well as volume for the same period. The report also includes production capacity statistics for the same period.
Geographic Segmentation
The report offers exhaustive assessment of different region-wise Choroidal Neovascularization Drug markets such as North America, Europe, China and Japan, etc. Key regions covered in the report are U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, UAE
For the period 2016-2027, the report provides country-wise revenue and volume sales analysis and region-wise revenue and volume analysis of the global Choroidal Neovascularization Drug market. For the period 2016-2021, it provides sales (consumption) analysis and forecast of different regional markets by each application as well as type segment in terms of volume.
Manufacturers
The report includes comprehensive company profiling of leading and emerging companies competing in the global Choroidal Neovascularization Drug market. It provides a detailed list of players operating at a global level. The players have been listed according to the type of products they offer in the global Choroidal Neovascularization Drug market and other factors. As part of the company profiling, the analysts authoring the report has provided the market entry year of each player considered for the research study. The report also offers extensive price, volume sales, and revenue analysis by the manufacturer at the global level for the period 2016-2021.
By Type and Application Segments
The report includes a detailed analysis of leading and type and application segments of the global Choroidal Neovascularization Drug market. All of the segments covered in the report are broadly analyzed based on some deciding factors. The segmental analysis section of the report offers revenue sales analysis and forecast of the global Choroidal Neovascularization Drug market by each type segment for the period 2016-2027. It also offers volume sales (consumption) analysis and forecast of the global Choroidal Neovascularization Drug market by each type segment for the same period. Also, it provides volume sales (consumption) analysis and forecast of the global Choroidal Neovascularization Drug market by each application segment for the same period.
This report includes the following manufacturers:
Cellphire, Inc.
Chrysalis BioTherapeutics, Inc.
Cleveland BioLabs, Inc.
Cumberland Pharmaceuticals, Inc.
Diffusion Pharmaceuticals Inc.
Eli Lilly and Company
GNI Group Ltd.
Humanetics Corporation
INSYS Therapeutics, Inc.
Meabco A/S
Neumedicines Inc.
Onconova Therapeutics, Inc.
PharmaIN Corporation
Pluristem Therapeutics Inc.
ProCertus BioPharm Inc.
RDD Pharma Ltd.
RedHill Biopharma Ltd.
RxBio, Inc.
Soligenix, Inc.
Market Segment by Type
AVMOC-001
BB-3
BBT-007
DG-3
Entolimod
EWA-001
Others
Market Segment by Application
Clinic
Hospital
Others
Research Methodology
To compile the detailed study of the global Choroidal Neovascularization Drug market, a robust research methodology has been adopted that aids in determining the key insights and also evaluates the growth prospects of the Choroidal Neovascularization Drug market. LBI Research analysts have conducted in-depth primary and secondary research to obtain crucial insights into the Choroidal Neovascularization Drug market. To carry out secondary research, the analysts have collected the information through company annual reports, journals, company press releases, and paid databases that were referred to gain and identify better opportunities in the global market.
In terms of production side, this report researches the Choroidal Neovascularization Drug production capacity, value, ex-factory price, growth rate, market share by manufacturers, regions (or countries) and by Type.
In terms of consumption side, this report focuses on the consumption of Choroidal Neovascularization Drug by regions (countries) and by Application.
The global Choroidal Neovascularization Drug market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of production analysis, the authors of the report have provided reliable estimations and calculations for global revenue and volume by Type segment of the global Choroidal Neovascularization Drug market. These figures have been provided in terms of both revenue and volume for the period 2016-2027. Additionally, the report provides accurate figures for production by region in terms of revenue as well as volume for the same period. The report also includes production capacity statistics for the same period.
Geographic Segmentation
The report offers exhaustive assessment of different region-wise Choroidal Neovascularization Drug markets such as North America, Europe, China and Japan, etc. Key regions covered in the report are U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, UAE
For the period 2016-2027, the report provides country-wise revenue and volume sales analysis and region-wise revenue and volume analysis of the global Choroidal Neovascularization Drug market. For the period 2016-2021, it provides sales (consumption) analysis and forecast of different regional markets by each application as well as type segment in terms of volume.
Manufacturers
The report includes comprehensive company profiling of leading and emerging companies competing in the global Choroidal Neovascularization Drug market. It provides a detailed list of players operating at a global level. The players have been listed according to the type of products they offer in the global Choroidal Neovascularization Drug market and other factors. As part of the company profiling, the analysts authoring the report has provided the market entry year of each player considered for the research study. The report also offers extensive price, volume sales, and revenue analysis by the manufacturer at the global level for the period 2016-2021.
By Type and Application Segments
The report includes a detailed analysis of leading and type and application segments of the global Choroidal Neovascularization Drug market. All of the segments covered in the report are broadly analyzed based on some deciding factors. The segmental analysis section of the report offers revenue sales analysis and forecast of the global Choroidal Neovascularization Drug market by each type segment for the period 2016-2027. It also offers volume sales (consumption) analysis and forecast of the global Choroidal Neovascularization Drug market by each type segment for the same period. Also, it provides volume sales (consumption) analysis and forecast of the global Choroidal Neovascularization Drug market by each application segment for the same period.
This report includes the following manufacturers:
Cellphire, Inc.
Chrysalis BioTherapeutics, Inc.
Cleveland BioLabs, Inc.
Cumberland Pharmaceuticals, Inc.
Diffusion Pharmaceuticals Inc.
Eli Lilly and Company
GNI Group Ltd.
Humanetics Corporation
INSYS Therapeutics, Inc.
Meabco A/S
Neumedicines Inc.
Onconova Therapeutics, Inc.
PharmaIN Corporation
Pluristem Therapeutics Inc.
ProCertus BioPharm Inc.
RDD Pharma Ltd.
RedHill Biopharma Ltd.
RxBio, Inc.
Soligenix, Inc.
Market Segment by Type
AVMOC-001
BB-3
BBT-007
DG-3
Entolimod
EWA-001
Others
Market Segment by Application
Clinic
Hospital
Others
Research Methodology
To compile the detailed study of the global Choroidal Neovascularization Drug market, a robust research methodology has been adopted that aids in determining the key insights and also evaluates the growth prospects of the Choroidal Neovascularization Drug market. LBI Research analysts have conducted in-depth primary and secondary research to obtain crucial insights into the Choroidal Neovascularization Drug market. To carry out secondary research, the analysts have collected the information through company annual reports, journals, company press releases, and paid databases that were referred to gain and identify better opportunities in the global market.
1 Report Overview
1.1 Research Scope
1.2 Market Segment by Type
1.2.1 Global Choroidal Neovascularization Drug Market Size Growth Rate by Type
1.2.2 AVMOC-001
1.2.3 BB-3
1.2.4 BBT-007
1.2.5 DG-3
1.2.6 Entolimod
1.2.7 EWA-001
1.2.8 Others
1.3 Market Segment by Application
1.3.1 Global Choroidal Neovascularization Drug Market Share by Application (2016 VS 2021 VS 2027)
1.3.2 Clinic
1.3.3 Hospital
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Market Perspective
2.1 Global Choroidal Neovascularization Drug Market Size (2016-2027)
2.1.1 Global Choroidal Neovascularization Drug Revenue (2016-2027)
2.1.2 Global Choroidal Neovascularization Drug Sales (2016-2027)
2.2 Global Choroidal Neovascularization Drug Market Size across Key Geographies Worldwide: 2016 VS 2021 VS 2027
2.2.1 Global Choroidal Neovascularization Drug Sales by Regions (2016-2021)
2.2.2 Global Choroidal Neovascularization Drug Revenue by Regions (2016-2021)
2.3 Global Choroidal Neovascularization Drug Market Size Forecast by Region
2.3.1 Global Choroidal Neovascularization Drug Sales Forecast by Region (2022-2027)
2.3.2 Global Choroidal Neovascularization Drug Revenue Forecast by Region (2022-2027)
2.4 Global Top Choroidal Neovascularization Drug Regions (Countries) Ranking by Market Size
2.5 Choroidal Neovascularization Drug Industry Trends
2.5.1 Choroidal Neovascularization Drug Market Trends
2.5.2 Choroidal Neovascularization Drug Market Drivers
2.5.3 Choroidal Neovascularization Drug Market Challenges
2.5.4 Choroidal Neovascularization Drug Market Restraints
3 Competitive Landscape by Manufacturers
3.1 Global Top Choroidal Neovascularization Drug Manufacturers by Sales (2016-2021)
3.1.1 Global Choroidal Neovascularization Drug Sales by Manufacturers (2016-2021)
3.1.2 Global Choroidal Neovascularization Drug Sales Market Share by Manufacturers (2016-2021)
3.1.3 Global 5 and 10 Largest Manufacturers by Choroidal Neovascularization Drug Sales in 2020
3.2 Global Top Manufacturers Choroidal Neovascularization Drug by Revenue
3.2.1 Global Choroidal Neovascularization Drug Revenue by Manufacturers (2016-2021)
3.2.2 Top Choroidal Neovascularization Drug Manufacturers Covered: Ranking by Revenue
3.2.3 Global Choroidal Neovascularization Drug Revenue Share by Manufacturers (2016-2021)
3.2.4 Global Choroidal Neovascularization Drug Market Concentration Ratio (CR5 and HHI)
3.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Choroidal Neovascularization Drug as of 2020)
3.4 Global Choroidal Neovascularization Drug Average Selling Price (ASP) by Manufacturers
3.5 Key Manufacturers Choroidal Neovascularization Drug Plants/Factories Distribution and Area Served
3.6 Date of Key Manufacturers Enter into Choroidal Neovascularization Drug Market
3.7 Key Manufacturers Choroidal Neovascularization Drug Product Offered
3.8 Mergers & Acquisitions, Expansion Plans
4 Global Choroidal Neovascularization Drug Market Size by Type
4.1 Global Choroidal Neovascularization Drug Historic Market Review by Type (2016-2021)
4.1.1 Global Choroidal Neovascularization Drug Sales Market Share by Type (2016-2021)
4.1.2 Global Choroidal Neovascularization Drug Revenue Market Share by Type (2016-2021)
4.1.3 Choroidal Neovascularization Drug Price by Type (2016-2021)
4.2 Global Choroidal Neovascularization Drug Market Estimates and Forecasts by Type (2022-2027)
4.2.1 Global Choroidal Neovascularization Drug Sales Forecast by Type (2022-2027)
4.2.2 Global Choroidal Neovascularization Drug Revenue Forecast by Type (2022-2027)
4.2.3 Choroidal Neovascularization Drug Price Forecast by Type (2022-2027)
5 Global Choroidal Neovascularization Drug Market Size by Application
5.1 Global Choroidal Neovascularization Drug Historic Market Review by Application (2016-2021)
5.1.1 Global Choroidal Neovascularization Drug Sales Market Share by Application (2016-2021)
5.1.2 Global Choroidal Neovascularization Drug Revenue Market Share by Application (2016-2021)
5.1.3 Choroidal Neovascularization Drug Price by Application (2016-2021)
5.2 Global Choroidal Neovascularization Drug Market Estimates and Forecasts by Application (2022-2027)
5.2.1 Global Choroidal Neovascularization Drug Sales Forecast by Application (2022-2027)
5.2.2 Global Choroidal Neovascularization Drug Revenue Forecast by Application (2022-2027)
5.2.3 Choroidal Neovascularization Drug Price Forecast by Application (2022-2027)
6 North America
6.1 North America Choroidal Neovascularization Drug Sales Breakdown by Company
6.1.1 North America Choroidal Neovascularization Drug Sales by Company (2016-2027)
6.1.2 North America Choroidal Neovascularization Drug Revenue by Company (2016-2027)
6.2 North America Choroidal Neovascularization Drug Market Size by Type (2016-2027)
6.2.1 North America Choroidal Neovascularization Drug Sales by Type (2016-2027)
6.2.2 North America Choroidal Neovascularization Drug Revenue by Type (2016-2027)
6.3 North America Choroidal Neovascularization Drug Market Size by Application (2016-2027)
6.3.1 North America Choroidal Neovascularization Drug Sales by Application (2016-2027)
6.3.2 North America Choroidal Neovascularization Drug Revenue by Application (2016-2027)
6.4 North America Choroidal Neovascularization Drug Market Size by Country
6.4.1 North America Choroidal Neovascularization Drug Sales by Country (2016-2027)
6.4.2 North America Choroidal Neovascularization Drug Revenue by Country (2016-2027)
6.4.3 U.S.
6.4.4 Canada
7 Europe
7.1 Europe Choroidal Neovascularization Drug Sales Breakdown by Company
7.1.1 Europe Choroidal Neovascularization Drug Sales by Company (2016-2027)
7.1.2 Europe Choroidal Neovascularization Drug Revenue by Company (2016-2027)
7.2 Europe Choroidal Neovascularization Drug Market Size by Type (2016-2027)
7.2.1 Europe Choroidal Neovascularization Drug Sales by Type (2016-2027)
7.2.2 Europe Choroidal Neovascularization Drug Revenue by Type (2016-2027)
7.3 Europe Choroidal Neovascularization Drug Market Size by Application (2016-2027)
7.3.1 Europe Choroidal Neovascularization Drug Sales by Application (2016-2027)
7.3.2 Europe Choroidal Neovascularization Drug Revenue by Application (2016-2027)
7.4 Europe Choroidal Neovascularization Drug Market Size by Country
7.4.1 Europe Choroidal Neovascularization Drug Sales by Country (2016-2027)
7.4.2 Europe Choroidal Neovascularization Drug Revenue by Country (2016-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
8 Asia Pacific
8.1 Asia Pacific Choroidal Neovascularization Drug Sales Breakdown by Company
8.1.1 Asia Pacific Choroidal Neovascularization Drug Sales by Company (2016-2027)
8.1.2 Asia Pacific Choroidal Neovascularization Drug Revenue by Company (2016-2027)
8.2 Asia Pacific Choroidal Neovascularization Drug Market Size by Type (2016-2027)
8.2.1 Asia Pacific Choroidal Neovascularization Drug Sales by Type (2016-2027)
8.2.2 Asia Pacific Choroidal Neovascularization Drug Revenue by Type (2016-2027)
8.3 Asia Pacific Choroidal Neovascularization Drug Market Size by Application (2016-2027)
8.3.1 Asia Pacific Choroidal Neovascularization Drug Sales by Application (2016-2027)
8.3.2 Asia Pacific Choroidal Neovascularization Drug Revenue by Application (2016-2027)
8.4 Asia Pacific Choroidal Neovascularization Drug Market Size by Regions
8.4.1 Asia Pacific Choroidal Neovascularization Drug Sales by Regions
8.4.2 Asia Pacific Choroidal Neovascularization Drug Revenue by Regions
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 India
8.4.7 Australia
8.4.8 Taiwan
8.4.9 Indonesia
8.4.10 Thailand
8.4.11 Malaysia
8.4.12 Philippines
8.4.13 Vietnam
9 Latin America
9.1 Latin America Choroidal Neovascularization Drug Sales Breakdown by Company
9.1.1 Latin America Choroidal Neovascularization Drug Sales by Company (2016-2027)
9.1.2 Latin America Choroidal Neovascularization Drug Revenue by Company (2016-2027)
9.2 Latin America Choroidal Neovascularization Drug Market Size by Type (2016-2027)
9.2.1 Latin America Choroidal Neovascularization Drug Sales by Type (2016-2027)
9.2.2 Latin America Choroidal Neovascularization Drug Revenue by Type (2016-2027)
9.3 Latin America Choroidal Neovascularization Drug Market Size by Application (2016-2027)
9.3.1 Latin America Choroidal Neovascularization Drug Sales by Application (2016-2027)
9.3.2 Latin America Choroidal Neovascularization Drug Revenue by Application (2016-2027)
9.4 Latin America Choroidal Neovascularization Drug Market Size by Country
9.4.1 Latin America Choroidal Neovascularization Drug Sales by Country (2016-2027)
9.4.2 Latin America Choroidal Neovascularization Drug Revenue by Country (2016-2027)
9.4.3 Mexico
9.4.4 Brazil
9.4.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Choroidal Neovascularization Drug Sales Breakdown by Company
10.1.1 Middle East and Africa Choroidal Neovascularization Drug Sales by Company (2016-2027)
10.1.2 Middle East and Africa Choroidal Neovascularization Drug Revenue by Company (2016-2027)
10.2 Middle East and Africa Choroidal Neovascularization Drug Market Size by Type (2016-2027)
10.2.1 Middle East and Africa Choroidal Neovascularization Drug Sales by Type (2016-2027)
10.2.2 Middle East and Africa Choroidal Neovascularization Drug Revenue by Type (2016-2027)
10.3 Middle East and Africa Choroidal Neovascularization Drug Market Size by Application (2016-2027)
10.3.1 Middle East and Africa Choroidal Neovascularization Drug Sales by Application (2016-2027)
10.3.2 Middle East and Africa Choroidal Neovascularization Drug Revenue by Application (2016-2027)
10.4 Middle East and Africa Choroidal Neovascularization Drug Market Size by Country
10.4.1 Middle East and Africa Choroidal Neovascularization Drug Sales by Country (2016-2027)
10.4.2 Middle East and Africa Choroidal Neovascularization Drug Revenue by Country (2016-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Company Profiles
11.1 Cellphire, Inc.
11.1.1 Cellphire, Inc. Corporation Information
11.1.2 Cellphire, Inc. Overview
11.1.3 Cellphire, Inc. Choroidal Neovascularization Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.1.4 Cellphire, Inc. Choroidal Neovascularization Drug Products and Services
11.1.5 Cellphire, Inc. Choroidal Neovascularization Drug SWOT Analysis
11.1.6 Cellphire, Inc. Recent Developments
11.2 Chrysalis BioTherapeutics, Inc.
11.2.1 Chrysalis BioTherapeutics, Inc. Corporation Information
11.2.2 Chrysalis BioTherapeutics, Inc. Overview
11.2.3 Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.2.4 Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Products and Services
11.2.5 Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug SWOT Analysis
11.2.6 Chrysalis BioTherapeutics, Inc. Recent Developments
11.3 Cleveland BioLabs, Inc.
11.3.1 Cleveland BioLabs, Inc. Corporation Information
11.3.2 Cleveland BioLabs, Inc. Overview
11.3.3 Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.3.4 Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Products and Services
11.3.5 Cleveland BioLabs, Inc. Choroidal Neovascularization Drug SWOT Analysis
11.3.6 Cleveland BioLabs, Inc. Recent Developments
11.4 Cumberland Pharmaceuticals, Inc.
11.4.1 Cumberland Pharmaceuticals, Inc. Corporation Information
11.4.2 Cumberland Pharmaceuticals, Inc. Overview
11.4.3 Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.4.4 Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Products and Services
11.4.5 Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug SWOT Analysis
11.4.6 Cumberland Pharmaceuticals, Inc. Recent Developments
11.5 Diffusion Pharmaceuticals Inc.
11.5.1 Diffusion Pharmaceuticals Inc. Corporation Information
11.5.2 Diffusion Pharmaceuticals Inc. Overview
11.5.3 Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.5.4 Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Products and Services
11.5.5 Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug SWOT Analysis
11.5.6 Diffusion Pharmaceuticals Inc. Recent Developments
11.6 Eli Lilly and Company
11.6.1 Eli Lilly and Company Corporation Information
11.6.2 Eli Lilly and Company Overview
11.6.3 Eli Lilly and Company Choroidal Neovascularization Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.6.4 Eli Lilly and Company Choroidal Neovascularization Drug Products and Services
11.6.5 Eli Lilly and Company Choroidal Neovascularization Drug SWOT Analysis
11.6.6 Eli Lilly and Company Recent Developments
11.7 GNI Group Ltd.
11.7.1 GNI Group Ltd. Corporation Information
11.7.2 GNI Group Ltd. Overview
11.7.3 GNI Group Ltd. Choroidal Neovascularization Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.7.4 GNI Group Ltd. Choroidal Neovascularization Drug Products and Services
11.7.5 GNI Group Ltd. Choroidal Neovascularization Drug SWOT Analysis
11.7.6 GNI Group Ltd. Recent Developments
11.8 Humanetics Corporation
11.8.1 Humanetics Corporation Corporation Information
11.8.2 Humanetics Corporation Overview
11.8.3 Humanetics Corporation Choroidal Neovascularization Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.8.4 Humanetics Corporation Choroidal Neovascularization Drug Products and Services
11.8.5 Humanetics Corporation Choroidal Neovascularization Drug SWOT Analysis
11.8.6 Humanetics Corporation Recent Developments
11.9 INSYS Therapeutics, Inc.
11.9.1 INSYS Therapeutics, Inc. Corporation Information
11.9.2 INSYS Therapeutics, Inc. Overview
11.9.3 INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.9.4 INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Products and Services
11.9.5 INSYS Therapeutics, Inc. Choroidal Neovascularization Drug SWOT Analysis
11.9.6 INSYS Therapeutics, Inc. Recent Developments
11.10 Meabco A/S
11.10.1 Meabco A/S Corporation Information
11.10.2 Meabco A/S Overview
11.10.3 Meabco A/S Choroidal Neovascularization Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.10.4 Meabco A/S Choroidal Neovascularization Drug Products and Services
11.10.5 Meabco A/S Choroidal Neovascularization Drug SWOT Analysis
11.10.6 Meabco A/S Recent Developments
11.11 Neumedicines Inc.
11.11.1 Neumedicines Inc. Corporation Information
11.11.2 Neumedicines Inc. Overview
11.11.3 Neumedicines Inc. Choroidal Neovascularization Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.11.4 Neumedicines Inc. Choroidal Neovascularization Drug Products and Services
11.11.5 Neumedicines Inc. Recent Developments
11.12 Onconova Therapeutics, Inc.
11.12.1 Onconova Therapeutics, Inc. Corporation Information
11.12.2 Onconova Therapeutics, Inc. Overview
11.12.3 Onconova Therapeutics, Inc. Choroidal Neovascularization Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.12.4 Onconova Therapeutics, Inc. Choroidal Neovascularization Drug Products and Services
11.12.5 Onconova Therapeutics, Inc. Recent Developments
11.13 PharmaIN Corporation
11.13.1 PharmaIN Corporation Corporation Information
11.13.2 PharmaIN Corporation Overview
11.13.3 PharmaIN Corporation Choroidal Neovascularization Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.13.4 PharmaIN Corporation Choroidal Neovascularization Drug Products and Services
11.13.5 PharmaIN Corporation Recent Developments
11.14 Pluristem Therapeutics Inc.
11.14.1 Pluristem Therapeutics Inc. Corporation Information
11.14.2 Pluristem Therapeutics Inc. Overview
11.14.3 Pluristem Therapeutics Inc. Choroidal Neovascularization Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.14.4 Pluristem Therapeutics Inc. Choroidal Neovascularization Drug Products and Services
11.14.5 Pluristem Therapeutics Inc. Recent Developments
11.15 ProCertus BioPharm Inc.
11.15.1 ProCertus BioPharm Inc. Corporation Information
11.15.2 ProCertus BioPharm Inc. Overview
11.15.3 ProCertus BioPharm Inc. Choroidal Neovascularization Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.15.4 ProCertus BioPharm Inc. Choroidal Neovascularization Drug Products and Services
11.15.5 ProCertus BioPharm Inc. Recent Developments
11.16 RDD Pharma Ltd.
11.16.1 RDD Pharma Ltd. Corporation Information
11.16.2 RDD Pharma Ltd. Overview
11.16.3 RDD Pharma Ltd. Choroidal Neovascularization Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.16.4 RDD Pharma Ltd. Choroidal Neovascularization Drug Products and Services
11.16.5 RDD Pharma Ltd. Recent Developments
11.17 RedHill Biopharma Ltd.
11.17.1 RedHill Biopharma Ltd. Corporation Information
11.17.2 RedHill Biopharma Ltd. Overview
11.17.3 RedHill Biopharma Ltd. Choroidal Neovascularization Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.17.4 RedHill Biopharma Ltd. Choroidal Neovascularization Drug Products and Services
11.17.5 RedHill Biopharma Ltd. Recent Developments
11.18 RxBio, Inc.
11.18.1 RxBio, Inc. Corporation Information
11.18.2 RxBio, Inc. Overview
11.18.3 RxBio, Inc. Choroidal Neovascularization Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.18.4 RxBio, Inc. Choroidal Neovascularization Drug Products and Services
11.18.5 RxBio, Inc. Recent Developments
11.19 Soligenix, Inc.
11.19.1 Soligenix, Inc. Corporation Information
11.19.2 Soligenix, Inc. Overview
11.19.3 Soligenix, Inc. Choroidal Neovascularization Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.19.4 Soligenix, Inc. Choroidal Neovascularization Drug Products and Services
11.19.5 Soligenix, Inc. Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Choroidal Neovascularization Drug Value Chain Analysis
12.2 Choroidal Neovascularization Drug Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Choroidal Neovascularization Drug Production Mode & Process
12.4 Choroidal Neovascularization Drug Sales and Marketing
12.4.1 Choroidal Neovascularization Drug Sales Channels
12.4.2 Choroidal Neovascularization Drug Distributors
12.5 Choroidal Neovascularization Drug Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
1.1 Research Scope
1.2 Market Segment by Type
1.2.1 Global Choroidal Neovascularization Drug Market Size Growth Rate by Type
1.2.2 AVMOC-001
1.2.3 BB-3
1.2.4 BBT-007
1.2.5 DG-3
1.2.6 Entolimod
1.2.7 EWA-001
1.2.8 Others
1.3 Market Segment by Application
1.3.1 Global Choroidal Neovascularization Drug Market Share by Application (2016 VS 2021 VS 2027)
1.3.2 Clinic
1.3.3 Hospital
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Market Perspective
2.1 Global Choroidal Neovascularization Drug Market Size (2016-2027)
2.1.1 Global Choroidal Neovascularization Drug Revenue (2016-2027)
2.1.2 Global Choroidal Neovascularization Drug Sales (2016-2027)
2.2 Global Choroidal Neovascularization Drug Market Size across Key Geographies Worldwide: 2016 VS 2021 VS 2027
2.2.1 Global Choroidal Neovascularization Drug Sales by Regions (2016-2021)
2.2.2 Global Choroidal Neovascularization Drug Revenue by Regions (2016-2021)
2.3 Global Choroidal Neovascularization Drug Market Size Forecast by Region
2.3.1 Global Choroidal Neovascularization Drug Sales Forecast by Region (2022-2027)
2.3.2 Global Choroidal Neovascularization Drug Revenue Forecast by Region (2022-2027)
2.4 Global Top Choroidal Neovascularization Drug Regions (Countries) Ranking by Market Size
2.5 Choroidal Neovascularization Drug Industry Trends
2.5.1 Choroidal Neovascularization Drug Market Trends
2.5.2 Choroidal Neovascularization Drug Market Drivers
2.5.3 Choroidal Neovascularization Drug Market Challenges
2.5.4 Choroidal Neovascularization Drug Market Restraints
3 Competitive Landscape by Manufacturers
3.1 Global Top Choroidal Neovascularization Drug Manufacturers by Sales (2016-2021)
3.1.1 Global Choroidal Neovascularization Drug Sales by Manufacturers (2016-2021)
3.1.2 Global Choroidal Neovascularization Drug Sales Market Share by Manufacturers (2016-2021)
3.1.3 Global 5 and 10 Largest Manufacturers by Choroidal Neovascularization Drug Sales in 2020
3.2 Global Top Manufacturers Choroidal Neovascularization Drug by Revenue
3.2.1 Global Choroidal Neovascularization Drug Revenue by Manufacturers (2016-2021)
3.2.2 Top Choroidal Neovascularization Drug Manufacturers Covered: Ranking by Revenue
3.2.3 Global Choroidal Neovascularization Drug Revenue Share by Manufacturers (2016-2021)
3.2.4 Global Choroidal Neovascularization Drug Market Concentration Ratio (CR5 and HHI)
3.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Choroidal Neovascularization Drug as of 2020)
3.4 Global Choroidal Neovascularization Drug Average Selling Price (ASP) by Manufacturers
3.5 Key Manufacturers Choroidal Neovascularization Drug Plants/Factories Distribution and Area Served
3.6 Date of Key Manufacturers Enter into Choroidal Neovascularization Drug Market
3.7 Key Manufacturers Choroidal Neovascularization Drug Product Offered
3.8 Mergers & Acquisitions, Expansion Plans
4 Global Choroidal Neovascularization Drug Market Size by Type
4.1 Global Choroidal Neovascularization Drug Historic Market Review by Type (2016-2021)
4.1.1 Global Choroidal Neovascularization Drug Sales Market Share by Type (2016-2021)
4.1.2 Global Choroidal Neovascularization Drug Revenue Market Share by Type (2016-2021)
4.1.3 Choroidal Neovascularization Drug Price by Type (2016-2021)
4.2 Global Choroidal Neovascularization Drug Market Estimates and Forecasts by Type (2022-2027)
4.2.1 Global Choroidal Neovascularization Drug Sales Forecast by Type (2022-2027)
4.2.2 Global Choroidal Neovascularization Drug Revenue Forecast by Type (2022-2027)
4.2.3 Choroidal Neovascularization Drug Price Forecast by Type (2022-2027)
5 Global Choroidal Neovascularization Drug Market Size by Application
5.1 Global Choroidal Neovascularization Drug Historic Market Review by Application (2016-2021)
5.1.1 Global Choroidal Neovascularization Drug Sales Market Share by Application (2016-2021)
5.1.2 Global Choroidal Neovascularization Drug Revenue Market Share by Application (2016-2021)
5.1.3 Choroidal Neovascularization Drug Price by Application (2016-2021)
5.2 Global Choroidal Neovascularization Drug Market Estimates and Forecasts by Application (2022-2027)
5.2.1 Global Choroidal Neovascularization Drug Sales Forecast by Application (2022-2027)
5.2.2 Global Choroidal Neovascularization Drug Revenue Forecast by Application (2022-2027)
5.2.3 Choroidal Neovascularization Drug Price Forecast by Application (2022-2027)
6 North America
6.1 North America Choroidal Neovascularization Drug Sales Breakdown by Company
6.1.1 North America Choroidal Neovascularization Drug Sales by Company (2016-2027)
6.1.2 North America Choroidal Neovascularization Drug Revenue by Company (2016-2027)
6.2 North America Choroidal Neovascularization Drug Market Size by Type (2016-2027)
6.2.1 North America Choroidal Neovascularization Drug Sales by Type (2016-2027)
6.2.2 North America Choroidal Neovascularization Drug Revenue by Type (2016-2027)
6.3 North America Choroidal Neovascularization Drug Market Size by Application (2016-2027)
6.3.1 North America Choroidal Neovascularization Drug Sales by Application (2016-2027)
6.3.2 North America Choroidal Neovascularization Drug Revenue by Application (2016-2027)
6.4 North America Choroidal Neovascularization Drug Market Size by Country
6.4.1 North America Choroidal Neovascularization Drug Sales by Country (2016-2027)
6.4.2 North America Choroidal Neovascularization Drug Revenue by Country (2016-2027)
6.4.3 U.S.
6.4.4 Canada
7 Europe
7.1 Europe Choroidal Neovascularization Drug Sales Breakdown by Company
7.1.1 Europe Choroidal Neovascularization Drug Sales by Company (2016-2027)
7.1.2 Europe Choroidal Neovascularization Drug Revenue by Company (2016-2027)
7.2 Europe Choroidal Neovascularization Drug Market Size by Type (2016-2027)
7.2.1 Europe Choroidal Neovascularization Drug Sales by Type (2016-2027)
7.2.2 Europe Choroidal Neovascularization Drug Revenue by Type (2016-2027)
7.3 Europe Choroidal Neovascularization Drug Market Size by Application (2016-2027)
7.3.1 Europe Choroidal Neovascularization Drug Sales by Application (2016-2027)
7.3.2 Europe Choroidal Neovascularization Drug Revenue by Application (2016-2027)
7.4 Europe Choroidal Neovascularization Drug Market Size by Country
7.4.1 Europe Choroidal Neovascularization Drug Sales by Country (2016-2027)
7.4.2 Europe Choroidal Neovascularization Drug Revenue by Country (2016-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
8 Asia Pacific
8.1 Asia Pacific Choroidal Neovascularization Drug Sales Breakdown by Company
8.1.1 Asia Pacific Choroidal Neovascularization Drug Sales by Company (2016-2027)
8.1.2 Asia Pacific Choroidal Neovascularization Drug Revenue by Company (2016-2027)
8.2 Asia Pacific Choroidal Neovascularization Drug Market Size by Type (2016-2027)
8.2.1 Asia Pacific Choroidal Neovascularization Drug Sales by Type (2016-2027)
8.2.2 Asia Pacific Choroidal Neovascularization Drug Revenue by Type (2016-2027)
8.3 Asia Pacific Choroidal Neovascularization Drug Market Size by Application (2016-2027)
8.3.1 Asia Pacific Choroidal Neovascularization Drug Sales by Application (2016-2027)
8.3.2 Asia Pacific Choroidal Neovascularization Drug Revenue by Application (2016-2027)
8.4 Asia Pacific Choroidal Neovascularization Drug Market Size by Regions
8.4.1 Asia Pacific Choroidal Neovascularization Drug Sales by Regions
8.4.2 Asia Pacific Choroidal Neovascularization Drug Revenue by Regions
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 India
8.4.7 Australia
8.4.8 Taiwan
8.4.9 Indonesia
8.4.10 Thailand
8.4.11 Malaysia
8.4.12 Philippines
8.4.13 Vietnam
9 Latin America
9.1 Latin America Choroidal Neovascularization Drug Sales Breakdown by Company
9.1.1 Latin America Choroidal Neovascularization Drug Sales by Company (2016-2027)
9.1.2 Latin America Choroidal Neovascularization Drug Revenue by Company (2016-2027)
9.2 Latin America Choroidal Neovascularization Drug Market Size by Type (2016-2027)
9.2.1 Latin America Choroidal Neovascularization Drug Sales by Type (2016-2027)
9.2.2 Latin America Choroidal Neovascularization Drug Revenue by Type (2016-2027)
9.3 Latin America Choroidal Neovascularization Drug Market Size by Application (2016-2027)
9.3.1 Latin America Choroidal Neovascularization Drug Sales by Application (2016-2027)
9.3.2 Latin America Choroidal Neovascularization Drug Revenue by Application (2016-2027)
9.4 Latin America Choroidal Neovascularization Drug Market Size by Country
9.4.1 Latin America Choroidal Neovascularization Drug Sales by Country (2016-2027)
9.4.2 Latin America Choroidal Neovascularization Drug Revenue by Country (2016-2027)
9.4.3 Mexico
9.4.4 Brazil
9.4.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Choroidal Neovascularization Drug Sales Breakdown by Company
10.1.1 Middle East and Africa Choroidal Neovascularization Drug Sales by Company (2016-2027)
10.1.2 Middle East and Africa Choroidal Neovascularization Drug Revenue by Company (2016-2027)
10.2 Middle East and Africa Choroidal Neovascularization Drug Market Size by Type (2016-2027)
10.2.1 Middle East and Africa Choroidal Neovascularization Drug Sales by Type (2016-2027)
10.2.2 Middle East and Africa Choroidal Neovascularization Drug Revenue by Type (2016-2027)
10.3 Middle East and Africa Choroidal Neovascularization Drug Market Size by Application (2016-2027)
10.3.1 Middle East and Africa Choroidal Neovascularization Drug Sales by Application (2016-2027)
10.3.2 Middle East and Africa Choroidal Neovascularization Drug Revenue by Application (2016-2027)
10.4 Middle East and Africa Choroidal Neovascularization Drug Market Size by Country
10.4.1 Middle East and Africa Choroidal Neovascularization Drug Sales by Country (2016-2027)
10.4.2 Middle East and Africa Choroidal Neovascularization Drug Revenue by Country (2016-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Company Profiles
11.1 Cellphire, Inc.
11.1.1 Cellphire, Inc. Corporation Information
11.1.2 Cellphire, Inc. Overview
11.1.3 Cellphire, Inc. Choroidal Neovascularization Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.1.4 Cellphire, Inc. Choroidal Neovascularization Drug Products and Services
11.1.5 Cellphire, Inc. Choroidal Neovascularization Drug SWOT Analysis
11.1.6 Cellphire, Inc. Recent Developments
11.2 Chrysalis BioTherapeutics, Inc.
11.2.1 Chrysalis BioTherapeutics, Inc. Corporation Information
11.2.2 Chrysalis BioTherapeutics, Inc. Overview
11.2.3 Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.2.4 Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Products and Services
11.2.5 Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug SWOT Analysis
11.2.6 Chrysalis BioTherapeutics, Inc. Recent Developments
11.3 Cleveland BioLabs, Inc.
11.3.1 Cleveland BioLabs, Inc. Corporation Information
11.3.2 Cleveland BioLabs, Inc. Overview
11.3.3 Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.3.4 Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Products and Services
11.3.5 Cleveland BioLabs, Inc. Choroidal Neovascularization Drug SWOT Analysis
11.3.6 Cleveland BioLabs, Inc. Recent Developments
11.4 Cumberland Pharmaceuticals, Inc.
11.4.1 Cumberland Pharmaceuticals, Inc. Corporation Information
11.4.2 Cumberland Pharmaceuticals, Inc. Overview
11.4.3 Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.4.4 Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Products and Services
11.4.5 Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug SWOT Analysis
11.4.6 Cumberland Pharmaceuticals, Inc. Recent Developments
11.5 Diffusion Pharmaceuticals Inc.
11.5.1 Diffusion Pharmaceuticals Inc. Corporation Information
11.5.2 Diffusion Pharmaceuticals Inc. Overview
11.5.3 Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.5.4 Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Products and Services
11.5.5 Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug SWOT Analysis
11.5.6 Diffusion Pharmaceuticals Inc. Recent Developments
11.6 Eli Lilly and Company
11.6.1 Eli Lilly and Company Corporation Information
11.6.2 Eli Lilly and Company Overview
11.6.3 Eli Lilly and Company Choroidal Neovascularization Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.6.4 Eli Lilly and Company Choroidal Neovascularization Drug Products and Services
11.6.5 Eli Lilly and Company Choroidal Neovascularization Drug SWOT Analysis
11.6.6 Eli Lilly and Company Recent Developments
11.7 GNI Group Ltd.
11.7.1 GNI Group Ltd. Corporation Information
11.7.2 GNI Group Ltd. Overview
11.7.3 GNI Group Ltd. Choroidal Neovascularization Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.7.4 GNI Group Ltd. Choroidal Neovascularization Drug Products and Services
11.7.5 GNI Group Ltd. Choroidal Neovascularization Drug SWOT Analysis
11.7.6 GNI Group Ltd. Recent Developments
11.8 Humanetics Corporation
11.8.1 Humanetics Corporation Corporation Information
11.8.2 Humanetics Corporation Overview
11.8.3 Humanetics Corporation Choroidal Neovascularization Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.8.4 Humanetics Corporation Choroidal Neovascularization Drug Products and Services
11.8.5 Humanetics Corporation Choroidal Neovascularization Drug SWOT Analysis
11.8.6 Humanetics Corporation Recent Developments
11.9 INSYS Therapeutics, Inc.
11.9.1 INSYS Therapeutics, Inc. Corporation Information
11.9.2 INSYS Therapeutics, Inc. Overview
11.9.3 INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.9.4 INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Products and Services
11.9.5 INSYS Therapeutics, Inc. Choroidal Neovascularization Drug SWOT Analysis
11.9.6 INSYS Therapeutics, Inc. Recent Developments
11.10 Meabco A/S
11.10.1 Meabco A/S Corporation Information
11.10.2 Meabco A/S Overview
11.10.3 Meabco A/S Choroidal Neovascularization Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.10.4 Meabco A/S Choroidal Neovascularization Drug Products and Services
11.10.5 Meabco A/S Choroidal Neovascularization Drug SWOT Analysis
11.10.6 Meabco A/S Recent Developments
11.11 Neumedicines Inc.
11.11.1 Neumedicines Inc. Corporation Information
11.11.2 Neumedicines Inc. Overview
11.11.3 Neumedicines Inc. Choroidal Neovascularization Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.11.4 Neumedicines Inc. Choroidal Neovascularization Drug Products and Services
11.11.5 Neumedicines Inc. Recent Developments
11.12 Onconova Therapeutics, Inc.
11.12.1 Onconova Therapeutics, Inc. Corporation Information
11.12.2 Onconova Therapeutics, Inc. Overview
11.12.3 Onconova Therapeutics, Inc. Choroidal Neovascularization Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.12.4 Onconova Therapeutics, Inc. Choroidal Neovascularization Drug Products and Services
11.12.5 Onconova Therapeutics, Inc. Recent Developments
11.13 PharmaIN Corporation
11.13.1 PharmaIN Corporation Corporation Information
11.13.2 PharmaIN Corporation Overview
11.13.3 PharmaIN Corporation Choroidal Neovascularization Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.13.4 PharmaIN Corporation Choroidal Neovascularization Drug Products and Services
11.13.5 PharmaIN Corporation Recent Developments
11.14 Pluristem Therapeutics Inc.
11.14.1 Pluristem Therapeutics Inc. Corporation Information
11.14.2 Pluristem Therapeutics Inc. Overview
11.14.3 Pluristem Therapeutics Inc. Choroidal Neovascularization Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.14.4 Pluristem Therapeutics Inc. Choroidal Neovascularization Drug Products and Services
11.14.5 Pluristem Therapeutics Inc. Recent Developments
11.15 ProCertus BioPharm Inc.
11.15.1 ProCertus BioPharm Inc. Corporation Information
11.15.2 ProCertus BioPharm Inc. Overview
11.15.3 ProCertus BioPharm Inc. Choroidal Neovascularization Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.15.4 ProCertus BioPharm Inc. Choroidal Neovascularization Drug Products and Services
11.15.5 ProCertus BioPharm Inc. Recent Developments
11.16 RDD Pharma Ltd.
11.16.1 RDD Pharma Ltd. Corporation Information
11.16.2 RDD Pharma Ltd. Overview
11.16.3 RDD Pharma Ltd. Choroidal Neovascularization Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.16.4 RDD Pharma Ltd. Choroidal Neovascularization Drug Products and Services
11.16.5 RDD Pharma Ltd. Recent Developments
11.17 RedHill Biopharma Ltd.
11.17.1 RedHill Biopharma Ltd. Corporation Information
11.17.2 RedHill Biopharma Ltd. Overview
11.17.3 RedHill Biopharma Ltd. Choroidal Neovascularization Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.17.4 RedHill Biopharma Ltd. Choroidal Neovascularization Drug Products and Services
11.17.5 RedHill Biopharma Ltd. Recent Developments
11.18 RxBio, Inc.
11.18.1 RxBio, Inc. Corporation Information
11.18.2 RxBio, Inc. Overview
11.18.3 RxBio, Inc. Choroidal Neovascularization Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.18.4 RxBio, Inc. Choroidal Neovascularization Drug Products and Services
11.18.5 RxBio, Inc. Recent Developments
11.19 Soligenix, Inc.
11.19.1 Soligenix, Inc. Corporation Information
11.19.2 Soligenix, Inc. Overview
11.19.3 Soligenix, Inc. Choroidal Neovascularization Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.19.4 Soligenix, Inc. Choroidal Neovascularization Drug Products and Services
11.19.5 Soligenix, Inc. Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Choroidal Neovascularization Drug Value Chain Analysis
12.2 Choroidal Neovascularization Drug Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Choroidal Neovascularization Drug Production Mode & Process
12.4 Choroidal Neovascularization Drug Sales and Marketing
12.4.1 Choroidal Neovascularization Drug Sales Channels
12.4.2 Choroidal Neovascularization Drug Distributors
12.5 Choroidal Neovascularization Drug Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
